Specifically, the inhibition of YAP1 activation and the subsequent reduction of already established tumors in vivo clearly demonstrate that YAP1 is a driver of tumor maintenance in malignant mesothelioma with the Hippo pathway or NF2 deletions. This evidence concerns the gene NF2 and malignant mesothelioma.